Bristol Myers Squibb Co. (BMY) stock forecast and price target
Price $63.43 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($63.43)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $6.44 | +4.8% | $50.2B |
| Next fiscal year ends December 31, 2027 | $6.70 | +4.0% | $48.8B |
| Next quarter ends December 31, 2026 | $1.50 | +19.0% | $12.7B |
| Quarter after ends March 31, 2027 | $1.52 | −3.7% | $11.2B |
Consensus of the analysts covering Bristol Myers Squibb, updated daily. In the last 30 days 0 estimates were raised and 26 lowered.
Our model vs. Wall Street
Analysts see 2.9% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Bristol Myers Squibb’s intrinsic value about 2% below today’s market value, and it scores 2.4 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.
Frequently asked questions
What is the Bristol Myers Squibb stock price target?
The average 12-month target from 24 analysts is $65.25, 2.9% above the current price of $63.43 Targets range from $40.00 to $80.00.
Is Bristol Myers Squibb a buy according to analysts?
The consensus rating is “Buy” (4 strong buy, 7 buy, 16 hold, 1 sell). Ratings are opinions, not guarantees; this is not investment advice.
How much is Bristol Myers Squibb expected to earn?
Analysts expect EPS of $6.44 for the fiscal year ending December 31, 2026 and $6.70 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.